FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115919377> ?p ?o ?g. }

• W2115919377 endingPage "2378" @default.
• W2115919377 startingPage "2372" @default.
• W2115919377 abstract "Limited data are available on the use of unboosted atazanavir in combination with nucleoside reverse transcriptase inhibitors (NRTIs) in treatment-experienced HIV-infected patients.We conducted a multicentre, retrospective study among patients with plasma HIV-1 RNA levels <50 copies/mL under antiretroviral therapy who switched to unboosted atazanavir + NRTIs between January 2002 and December 2008. Virological failure during follow-up was defined as a confirmed plasma HIV-1 RNA level >50 copies/mL. Baseline risk factors for virological failure were identified using Cox proportional hazards models.A total of 886 patients were analysed. At baseline, median age was 44 years, 71.5% were males and median CD4 cell count was 490 cells/mm(3). NRTIs used in combination with atazanavir were tenofovir, abacavir and emtricitabine/lamivudine in 36.9%, 44.1% and 94.4% of patients, respectively. Median follow-up was 21 months. The 3 year probability of virological failure was 20.1%. Only a history of virological failure under NRTIs [hazard ratio (HR) 1.63, P = 0.049] and under protease inhibitors (HR 2.04, P = 0.006) were significantly associated with the risk of virological failure. Among the 431 patients without a prior history of virological failure, the 3 year probability of virological failure was 11.3%, and only hepatitis C virus co-infection (HR 2.25, P = 0.026) and abacavir use (HR 0.43, P = 0.04) were associated with the risk of virological failure. Safety of the switch was satisfactory, with improvement of the lipid profile.In patients with virological suppression and no prior history of virological failure, a switch to unboosted atazanavir in combination with NRTIs is associated with a low probability of virological failure and a good safety profile." @default.
• W2115919377 created "2016-06-24" @default.
• W2115919377 creator A5002456130 @default.
• W2115919377 creator A5011035523 @default.
• W2115919377 creator A5022180654 @default.
• W2115919377 creator A5026779580 @default.
• W2115919377 creator A5029198983 @default.
• W2115919377 creator A5029770079 @default.
• W2115919377 creator A5031505042 @default.
• W2115919377 creator A5033592492 @default.
• W2115919377 creator A5034814001 @default.
• W2115919377 creator A5044171804 @default.
• W2115919377 creator A5049035721 @default.
• W2115919377 creator A5050409135 @default.
• W2115919377 creator A5066493529 @default.
• W2115919377 creator A5066933191 @default.
• W2115919377 creator A5068498977 @default.
• W2115919377 creator A5068517502 @default.
• W2115919377 creator A5069415410 @default.
• W2115919377 creator A5074373099 @default.
• W2115919377 creator A5074577164 @default.
• W2115919377 creator A5075357953 @default.
• W2115919377 date "2011-08-05" @default.
• W2115919377 modified "2023-10-02" @default.
• W2115919377 title "Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy" @default.
• W2115919377 cites W1697799723 @default.
• W2115919377 cites W1876352928 @default.
• W2115919377 cites W1979035566 @default.
• W2115919377 cites W1980690358 @default.
• W2115919377 cites W1988101744 @default.
• W2115919377 cites W1988633664 @default.
• W2115919377 cites W1997141231 @default.
• W2115919377 cites W2003213783 @default.
• W2115919377 cites W2024988708 @default.
• W2115919377 cites W2036891173 @default.
• W2115919377 cites W2046108360 @default.
• W2115919377 cites W2058217770 @default.
• W2115919377 cites W2076420181 @default.
• W2115919377 cites W2093847910 @default.
• W2115919377 cites W2117312836 @default.
• W2115919377 cites W2122503778 @default.
• W2115919377 cites W2147235996 @default.
• W2115919377 cites W2147357250 @default.
• W2115919377 cites W2318380357 @default.
• W2115919377 doi "https://doi.org/10.1093/jac/dkr316" @default.
• W2115919377 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21821627" @default.
• W2115919377 hasPublicationYear "2011" @default.
• W2115919377 type Work @default.
• W2115919377 sameAs 2115919377 @default.
• W2115919377 citedByCount "30" @default.
• W2115919377 countsByYear W21159193772012 @default.
• W2115919377 countsByYear W21159193772013 @default.
• W2115919377 countsByYear W21159193772014 @default.
• W2115919377 countsByYear W21159193772015 @default.
• W2115919377 countsByYear W21159193772016 @default.
• W2115919377 countsByYear W21159193772017 @default.
• W2115919377 countsByYear W21159193772018 @default.
• W2115919377 countsByYear W21159193772019 @default.
• W2115919377 countsByYear W21159193772021 @default.
• W2115919377 crossrefType "journal-article" @default.
• W2115919377 hasAuthorship W2115919377A5002456130 @default.
• W2115919377 hasAuthorship W2115919377A5011035523 @default.
• W2115919377 hasAuthorship W2115919377A5022180654 @default.
• W2115919377 hasAuthorship W2115919377A5026779580 @default.
• W2115919377 hasAuthorship W2115919377A5029198983 @default.
• W2115919377 hasAuthorship W2115919377A5029770079 @default.
• W2115919377 hasAuthorship W2115919377A5031505042 @default.
• W2115919377 hasAuthorship W2115919377A5033592492 @default.
• W2115919377 hasAuthorship W2115919377A5034814001 @default.
• W2115919377 hasAuthorship W2115919377A5044171804 @default.
• W2115919377 hasAuthorship W2115919377A5049035721 @default.
• W2115919377 hasAuthorship W2115919377A5050409135 @default.
• W2115919377 hasAuthorship W2115919377A5066493529 @default.
• W2115919377 hasAuthorship W2115919377A5066933191 @default.
• W2115919377 hasAuthorship W2115919377A5068498977 @default.
• W2115919377 hasAuthorship W2115919377A5068517502 @default.
• W2115919377 hasAuthorship W2115919377A5069415410 @default.
• W2115919377 hasAuthorship W2115919377A5074373099 @default.
• W2115919377 hasAuthorship W2115919377A5074577164 @default.
• W2115919377 hasAuthorship W2115919377A5075357953 @default.
• W2115919377 hasBestOaLocation W21159193772 @default.
• W2115919377 hasConcept C126322002 @default.
• W2115919377 hasConcept C142462285 @default.
• W2115919377 hasConcept C159047783 @default.
• W2115919377 hasConcept C207103383 @default.
• W2115919377 hasConcept C2522874641 @default.
• W2115919377 hasConcept C2776999253 @default.
• W2115919377 hasConcept C2777869810 @default.
• W2115919377 hasConcept C2778414717 @default.
• W2115919377 hasConcept C2779465607 @default.
• W2115919377 hasConcept C2779778239 @default.
• W2115919377 hasConcept C2779889181 @default.
• W2115919377 hasConcept C2780593183 @default.
• W2115919377 hasConcept C2993143319 @default.
• W2115919377 hasConcept C3013748606 @default.
• W2115919377 hasConcept C44249647 @default.
• W2115919377 hasConcept C71924100 @default.
• W2115919377 hasConcept C90924648 @default.

• next